New model more accurately classifies breast cancer risk
the ONA take:
Every year in America, more than a million women have breast biopsies that turn out to have benign findings. A new model, tested by a group of researchers led by Amy Degnim, M.D., a surgeon at Mayo Clinic, uses histologic features of biopsied breast tissue from benign findings along with demographic data to more accurately determine future breast cancer risk.
To test their new model, the investigators examined a cohort of approximately ten thousand women who received benign breast biopsy results from the Mayo Clinic but later developed breast cancer. The resulting age-specific incidence data was combined with a relative risk model created from both matched controls and 377 patients that later developed breast cancer.
Risk predictions from the new model were compared to the current standard, the Breast Cancer Risk Assessment Tool (BCRAT). The concordance statistic (both in the model development series and the validation series) was found to be higher in the new model than from the BCRAT.
A more accurate model for early breast cancer prediction could prove extremely useful, given that women with benign breast disease stand a higher risk of eventually developing breast cancer. This research was published in the Journal of Clinical Oncology.
Histologic features of biopsied breast tissue from benign findings along with demographic data to more accurately determine risk.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|